Original Article

You have free access to this content

Expression profiling of ependymomas unravels localization and tumor grade-specific tumorigenesis

Thomas Palm ChE¹,
Dominique Figarella-Branger MD, PhD²,
Françoise Chapon MD, PhD³,
Catherine Lacroix MD⁴,
Françoise Gray MD, PhD⁵,
Francesco Scaravilli MD, PhD⁶,
David W. Ellison MD, PhD⁷,
Isabelle Salmon MD, PhD⁸,
Miikka Vikkula MD, PhD^1,†,
Catherine Godfraind MD, PhD^9,†,‡,*

Article first published online: 17 JUN 2009

DOI: 10.1002/cncr.24476

Issue

Cancer

Volume 115, Issue 17, pages 3955–3968, 1 September 2009

Additional Information

How to Cite

Palm, T., Figarella-Branger, D., Chapon, F., Lacroix, C., Gray, F., Scaravilli, F., Ellison, D. W., Salmon, I., Vikkula, M. and Godfraind, C. (2009), Expression profiling of ependymomas unravels localization and tumor grade-specific tumorigenesis. Cancer, 115: 3955–3968. doi: 10.1002/cncr.24476

Author Information

¹
Laboratory of Human Molecular Genetics, Duve Institute, Catholic University of Louvain, Brussels, Belgium
²
Department of Pathology and Neuropathology, La Timone's Hospital, AP-HM and EA3281, University of the Mediterranean, Marseille, France
³
Laboratory of Pathology, CHU-Caen, Caen, France
⁴
Laboratory of Pathology, Hôpital Kremlin-Bicêtre, Paris, France
⁵
Department of Pathology, APHP Hôpital Lariboisière, Université Paris VII, Paris, France
⁶
Department of Neuropathology, Institute of Neurology, Queen Square, University College London, London, United Kingdom
⁷
Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee
⁸
Laboratory of Pathology, Erasmus University Hospital, Free University of Brussels, Brussels, Belgium
⁹
Neuroscience Center, Laboratory of Neuropathology, Catholic University of Louvain, Brussels, Belgium

^†
The last 2 authors contributed equally to this work.
^‡
Fax: (011) 32-2-764-74-60

Email: Catherine Godfraind MD, PhD (catherine.godfraind@uclouvain.be)

^*Laboratory of Pathology, Cliniques Universitaires St. Luc, Université Catholique de Louvain, Avenue Hippocrate, 10, 1200 Brussels, Belgium

Publication History

Issue published online: 20 AUG 2009
Article first published online: 17 JUN 2009
Manuscript Accepted: 5 FEB 2009
Manuscript Revised: 13 JAN 2009
Manuscript Received: 17 SEP 2008

Funded by

Fonds Maisin (UCL)
Fédération belge contre le cancer
Fonds pour la formation á la recherche dans l'industrie et l'agriculture

ARTICLE TOOLS

View Full Article (HTML) Get PDF (1653K)

References

1
LouisDN, OhgakiH, WiestlerOD, CaveneeWK, eds. WHO Classification of Tumors of the Central Nervous System. Lyon, France: IARC Press; 2007.
2
Hirose Y, Aldape K, Bollen A, et al. Chromosomal abnormalities subdivide ependymal tumors into clinically relevant groups. Am J Pathol. 2001; 158: 1137X-1143.
- CrossRef
3
Huang B, Starostik P, Schraut H, Krauss J, Sorensen N, Roggendorf W. Human ependymomas reveal frequent deletions on chromosomes 6 and 9. Acta Neuropathol (Berl). 2003; 106: 357-362.
4
Mazewski C, Soukup S, Ballard E, Gotwals B, Lampkin B. Karyotype studies in 18 ependymomas with literature review of 107 cases. Cancer Genet Cytogenet. 1999; 113: 1-8.
5
Vagner-Capodano AM, Zattara-Cannoni H, Gambarelli D, et al. Cytogenetic study of 33 ependymomas. Cancer Genet Cytogenet. 1999; 115: 96-99.
6
Zheng PP, Pang JC, Hui AB, Ng HK. Comparative genomic hybridization detects losses of chromosomes 22 and 16 as the most common recurrent genetic alterations in primary ependymomas. Cancer Genet Cytogenet. 2000; 122: 18-25.
7
Dyer S, Prebble E, Davison V, et al. Genomic imbalances in pediatric intracranial ependymomas define clinically relevant groups. Am J Pathol. 2002; 161: 2133-2141.
8
Carter M, Nicholson J, Ross F, et al. Genetic abnormalities detected in ependymomas by comparative genomic hybridisation. Br J Cancer. 2002; 86: 929-939.
9
Rousseau E, Palm T, Scaravilli F, et al. Trisomy 19 ependymoma, a newly recognized genetico-histological association, including clear cell ependymoma [serial online]. Mol Cancer. 2007; 6: 47.
10
Granzow M, Popp S, Weber S, et al. Isochromosome 1q as an early genetic event in a child with intracranial ependymoma characterized by molecular cytogenetics. Cancer Genet Cytogenet. 2001; 130: 79-83.
11
Mendrzyk F, Korshunov A, Benner A, et al. Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. Clin Cancer Res. 2006; 12( 7 pt 1): 2070-2079.
12
Rousseau E, Ruchoux MM, Scaravilli F, et al. CDKN2A, CDKN2B and p14ARF are frequently and differentially methylated in ependymal tumours. Neuropathol Appl Neurobiol. 2003; 29: 574-583.
Direct Link:
13
Korshunov A, Neben K, Wrobel G, et al. Gene expression patterns in ependymomas correlate with tumor location, grade, and patient age. Am J Pathol. 2003; 163: 1721-1727.
14
Modena P, Lualdi E, Facchinetti F, et al. Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. J Clin Oncol. 2006; 24: 5223-5233.
15
Taylor MD, Poppleton H, Fuller C, et al. Radial glia cells are candidate stem cells of ependymoma. Cancer Cell. 2005; 8: 323-335.
16
Lukashova VZI, Kneitz S, Monoranu CM, et al. Ependymoma gene expression profiles associated with histological subtype, proliferation, and patient survival. Acta Neuropathol (Berl). 2007; 113: 325-337.
17
Suarez-Merino B, Hubank M, Revesz T, et al. Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including 4 transcripts at 22q12.1-q13.3. Neuro Oncol. 2005; 7: 20-31.
18
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100: 57-70.
19
Tihan T, Zhou T, Holmes E, Burger PC, Ozuysal S, Rushing EJ. The prognostic value of histological grading of posterior fossa ependymomas in children: a Children's Oncology Group study and a review of prognostic factors. Mod Pathol. 2008; 21: 165-177.
- PubMed,
- Web of Science® Times Cited: 11
20
Zamecnik J, Snuderl M, Eckschlager T, et al. Pediatric intracranial ependymomas: prognostic relevance of histological, immunohistochemical, and flow cytometric factors. Mod Pathol. 2003; 16: 980-991.
21
Argiropoulos B, Humphries RK. Hox genes in hematopoiesis and leukemogenesis. Oncogene. 2007; 26: 6766-6776.
22
Cillo C, Cantile M, Faiella A, Boncinelli E. Homeobox genes in normal and malignant cells. J Cell Physiol. 2001; 188: 161-169.
Direct Link:
23
Katoh Y, Katoh M. Hedgehog signaling pathway and gastric cancer. Cancer Biol Ther. 2005; 4: 1050-1054.
24
Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer. 2003; 3: 895-902.
25
Zhang XP, Zheng G, Zou L, et al. Notch activation promotes cell proliferation and the formation of neural stem cell-like colonies in human glioma cells. Mol Cell Biochem. 2008; 307( 1-2): 101-108.
26
Ward EJ, Shcherbata HR, Reynolds SH, Fischer KA, Hatfield SD, Ruohola-Baker H. Stem cells signal to the niche through the Notch pathway in the Drosophila ovary. Curr Biol. 2006; 16: 2352-2358.
27
Hallahan AR, Pritchard JI, Hansen S, et al. The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res. 2004; 64: 7794-7800.
28
Deng H, Makizumi R, Ravikumar TS, Dong H, Yang W, Yang WL. Bone morphogenetic protein-4 is overexpressed in colonic adenocarcinomas and promotes migration and invasion of HCT116 cells. Exp Cell Res. 2007; 313: 1033-1044.
29
Piccirillo SG, Reynolds BA, Zanetti N, et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature. 2006; 444: 761-765.
30
Vandeputte DA, Troost D, Leenstra S, et al. Expression and distribution of id helix-loop-helix proteins in human astrocytic tumors. Glia. 2002; 38: 329-338.
Direct Link:
31
Cassimeris L. Cell division: eg'ing on microtubule flux. Curr Biol. 2004; 14: R1000-R1002.
32
Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004; 20: 781-810.
33
Taipale J, Beachy PA. The Hedgehog and Wnt signalling pathways in cancer. Nature. 2001; 411: 349-354.
34
Bennetto L, Foreman N, Harding B, et al. Ki-67 immunolabelling index is a prognostic indicator in childhood posterior fossa ependymomas. Neuropathol Appl Neurobiol. 1998; 24: 434-440.
Direct Link:
35
Ho DM, Hsu CY, Wong TT, Chiang H. A clinicopathologic study of 81 patients with ependymomas and proposal of diagnostic criteria for anaplastic ependymoma. J Neurooncol. 2001; 54: 77-85.
36
Coller HA, Forman JJ, Legesse-Miller A. “Myc'ed messages”: myc induces transcription of E2F1 while inhibiting its translation via a microRNA polycistron [serial online]. PLoS Genet. 2007; 3: e146.
- CrossRef,
- PubMed,
- CAS
37
Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000; 182: 311-322.
Direct Link:
38
Johnson DG, Cress WD, Jakoi L, Nevins JR. Oncogenic capacity of the E2F1 gene. Proc Natl Acad Sci U S A. 1994; 91: 12823-12827.
39
Johnson DG, Degregori J. Putting the oncogenic and tumor suppressive activities of E2F into context. Curr Mol Med. 2006; 6: 731-738.
40
Matsumura I, Tanaka H, Kanakura Y. E2F1 and c-Myc in cell growth and death. Cell Cycle. 2003; 2: 333-338.
- CrossRef,
- PubMed,
- CAS
41
Olson MV, Johnson DG, Jiang H, et al. Transgenic E2F1 expression in the mouse brain induces a human-like bimodal pattern of tumors. Cancer Res. 2007; 67: 4005-4009.
42
Preusser M, Wolfsberger S, Czech T, Slavc I, Budka H, Hainfellner JA. Survivin expression in intracranial ependymomas and its correlation with tumor cell proliferation and patient outcome. Am J Clin Pathol. 2005; 124: 543-549.
43
Easwaran V, Lee SH, Inge L, et al. Beta-catenin regulates vascular endothelial growth factor expression in colon cancer. Cancer Res. 2003; 63: 3145-3153.
44
Chan AS, Leung SY, Wong MP, et al. Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma. Am J Surg Pathol. 1998; 22: 816-826.
45
Preusser M, Wolfsberger S, Haberler C, et al. Vascularization and expression of hypoxia-related tissue factors in intracranial ependymoma and their impact on patient survival. Acta Neuropathol (Berl). 2005; 109: 211-216.
46
Hazan RB, Qiao R, Keren R, Badano I, Suyama K. Cadherin switch in tumor progression. Ann N Y Acad Sci. 2004; 1014: 155-163.
Direct Link:
47
Bringuier PP, Umbas R, Schaafsma HE, Karthaus HF, Debruyne FM, Schalken JA. Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res. 1993; 53: 3241-3245.
48
Michalowski MB, de Fraipont F, Michelland S, et al. Methylation of RASSF1A and TRAIL pathway-related genes is frequent in childhood intracranial ependymomas and benign choroid plexus papilloma. Cancer Genet Cytogenet. 2006; 166: 74-81.
49
Wagner TU. Bone morphogenetic protein signaling in stem cells—1 signal, many consequences. FEBS J. 2007; 274: 2968-2976.
Direct Link:
50
Akin ZN, Nazarali AJ. Hox genes and their candidate downstream targets in the developing central nervous system. Cell Mol Neurobiol. 2005; 25( 3-4): 697-741.
51
Bapat SA. Evolution of cancer stem cells. Semin Cancer Biol. 2007; 17: 204-213.

View Full Article (HTML) Get PDF (1653K)

JOURNAL TOOLS

JOURNAL MENU

FIND ISSUES

FIND ARTICLES

GET ACCESS

FOR CONTRIBUTORS

ABOUT THIS JOURNAL

SPECIAL FEATURES

Expression profiling of ependymomas unravels localization and tumor grade-specific tumorigenesis

Cancer

How to Cite

Author Information

Publication History

Funded by

ARTICLE TOOLS

References

More content like this

JOURNAL TOOLS

JOURNAL MENU

FIND ISSUES

FIND ARTICLES

GET ACCESS

FOR CONTRIBUTORS

ABOUT THIS JOURNAL

SPECIAL FEATURES

Expression profiling of ependymomas unravels localization and tumor grade-specific tumorigenesis

Cancer

How to Cite

Author Information

Publication History

Funded by

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

References

More content like this